Company news
Canton Strategic Holdings, Inc. (NASDAQ:CNTN) news
Every Canton Strategic Holdings, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Canton Strategic Holdings, Inc. Releases Second Quarter 2026 Financial and Operational Results
August 14, 2026
Three New Directors Elected to the Board of Canton Strategic Holdings, Inc.
July 28, 2026
Canton Strategic Holdings, Inc. Announces Sale of Gravitas Life Sciences, LLC
July 23, 2026
Canton Strategic Holdings, Inc. Announces Launch of Locking Service to Support Network Infrastructure Providers
June 23, 2026
Canton Strategic Holdings Reports First Quarter 2026 Financial and Operational Results
May 13, 2026
Canton Strategic Holdings, Inc. Presents Quarterly Canton Network Ecosystem Update
April 20, 2026
Canton Strategic Holdings Reports Full Year 2025 Financial and Operational Results
March 31, 2026
Canton Strategic Holdings, Inc. Chairman and CEO Mark Wendland Elected to Canton Foundation Board
March 3, 2026
Tharimmune, Inc. Announces Corporate Rebrand to Canton Strategic Holdings, Inc., Marking Milestone in Canton Network Digital Asset Treasu...
February 17, 2026
Tharimmune, Inc. Announces Closing of $55 Million Underwritten Registered Direct Offering
January 22, 2026
Tharimmune, Inc. Announces Pricing of $55 Million Underwritten Registered Offering
January 20, 2026
Tharimmune, Inc. Appoints Jacob Asbury as Chief Financial Officer to Advance Canton Coin Treasury Strategy
December 12, 2025
Tharimmune, Inc. Closes $545 Million Private Placement to Establish Canton Coin Treasury Strategy
November 6, 2025
Tharimmune, Inc. Announces Private Placement of Approximately $540 Million Led by DRW and Liberty City Ventures to Establish Canton Coin ...
November 3, 2025
Tharimmune Announces Pricing of $1.74 Million Registered Direct Public Offering of Common Stock and Warrants
July 23, 2025
Tharimmune Announces Key Leadership Appointments Including James Gordon Liddy Joining Board of Directors
June 17, 2025
Tharimmune Appoints Clay Kahler and Gary Stetz to its Board of Directors
April 30, 2025
Tharimmune Announces Option Agreement for Key Technologies for Generating HER2/HER3 Antibody Drug Conjugates (ADCs)
April 23, 2024